Uterine (Endometrial) Cancer Clinical Trials
Uterine cancer clinical trials are conducted at Moffitt Cancer Center, where we continue to lead the way in researching and developing new and better treatments for all forms of cancer. At a single location, our patients have access to the latest treatment options, including promising new clinical trials, as well as advice, support and outstanding care from board-certified physicians. Any interested patient is welcome to consult with our team of experts – with or without a referral – to learn about available treatment options and find out if she is eligible to participate in a clinical trial.
Should You Consider a Uterine Cancer Clinical Trial?
Many prospective clinical trial participants are naturally concerned about safety, and often ask how a patient will be protected if she decides to take part. At Moffitt, each clinical trial is developed in accordance with a research plan, or protocol. The protocol for uterine cancer clinical trials, which is designed to protect the health, safety and well-being of participants, outlines:
- What the study is intended to accomplish
- How the study will achieve its goals
- Why the study is being performed
Additionally, each proposed study must adhere to strict guidelines, and its compliance is continually monitored by an Institutional Review Board (IRB). An IRB is an independent ethics committee that is formally designated to review and monitor the progress of medical research to ensure that participants are continually protected.
Clinical Trials at Moffitt Cancer Center
At Moffitt, we continue to make significant progress in researching and developing new cancer treatments. In recognition of our efforts, Moffitt has been designated a Comprehensive Cancer Center by the National Cancer Institute. Through our robust clinical trial offerings, we are able to make promising experimental therapies available to patients who qualify, and our multispecialty team of uterine cancer experts ensures the best possible care for each patient.
If you’d like to discuss uterine cancer clinical trials with the team of clinical trial navigators, please call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.
-
Clinical Trials
CLINICAL TRIAL 20870
Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors
Condition: Gynecological Tumor
Intervention: Aspirin/Placebo (); Avastin (Bevacizumab); Bevacizumab (); Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin (); paclitaxel ()
CLINICAL TRIAL 22102
A Phase 1/2, First in Human Multicenter Study of Emi-Le in Patients with Solid Tumors
Condition: Multiple
Intervention: Emiltatug Ledadotin (); XMT-1660 ()
CLINICAL TRIAL 23067
Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-positive Endometrioid Endometrial Cancers
Condition: Gynecological Tumor
Intervention: Alpelisib (); Faslodex (fulvestrant); fulvestrant ()
CLINICAL TRIAL 23143
Trends and Outcomes in HIV-positive Patients Undergoing Treatment for Invasive or Preinvasive Cervical and Other Gynecologic Neoplasias
Condition: Gynecological Tumor
Intervention:
CLINICAL TRIAL 23176
A Phase 2, randomised, open label, multicentre study of an intraperitoneal alpha-emitting radionuclide therapy (Radspherin®) in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer, with peritoneal metastasis that are homologous recombination proficient and scheduled to undergo neoadjuvant chemotherapy and interval debulking surgery
Condition: Gynecological Tumor
Intervention: Radspherin ()
CLINICAL TRIAL 23362
DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer
Condition: Gynecological Tumor
Intervention: Paraplatin (carboplatin); Pembrolizumab (Keytruda); Rilvegostomig (); T-Dxd (); Taxol (paclitaxel); carboplatin (); paclitaxel ()
CLINICAL TRIAL 23380
A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod CAR T Protducts in Heterozygous HLA-A*02 Adult with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Condition: Thoracic
Intervention: A2B543 (); A2B694 (); IL-2 (Interleukin-2); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
CLINICAL TRIAL 23636
A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors
Condition: Gynecological Tumor
Intervention: XmAb541 ()
CLINICAL TRIAL 23645
PHASE 1 DOSE ESCALATION AND EXPANSION STUDY OF XB628 AS A SINGLE AGENT AND IN COMBINATION WITH ZANZALINTINIB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Condition: Multiple
Intervention: XB628 (); Zanzalintinib ()
CLINICAL TRIAL 23697
A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Olomorasib (); Sotorasib (); Trametinib (); VVD-159642 ()
CLINICAL TRIAL 24028
OMNIRAY, A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults with GRPR-Positive Advanced Solid Tumors
Condition: Multiple
Intervention: Abemaciclib (); Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Exemestane (); Faslodex (fulvestrant); Femara (Letrozole); Imlunestrant (); LY2835219 (Abemaciclib); LY4257496 (); LY4257529 (); Letrozole (); Xeloda (capecitabine); capecitabine (); fulvestrant ()
CLINICAL TRIAL 24081
A Phase 1 Study of SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR, in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma
Condition: Multiple
Intervention: SynKIR-110 ()
CLINICAL TRIAL 24190
A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy with LY4337713 in Adults with FAP-Positive Solid Tumors (FiREBOLT)
Condition: Multiple
Intervention: LY4337713 (); [18F] FAPI-74 (); [Ga-68]-FAPI-46 ()
CLINICAL TRIAL 24236
A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: 5-fluorouracil (); Alimta (Pemetrexed); ERAS-0015 (); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Oxaliplatin (); Panitumumab (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxotere (docetaxel); Vectibix (Panitumumab); carboplatin (); cisplatin (); docetaxel (); eloxatin (Oxaliplatin); gemcitabine (); leucovorin ()
CLINICAL TRIAL 24299
A study of a mutant-selective inhibitor, CGT6297, in patients with advanced solid tumors harboring PIK3CA mutations
Condition: Multiple
Intervention: CGT6297 ()